ADC Therapeutics SA expected to post a loss of 29 cents a share - Earnings Preview

ADC Therapeutics SA

24/02/2023 14:04

* ADC Therapeutics SA  ADCT.N   ADCT.K  is expected to show
a rise
in quarterly revenue when it reports  results on February 28. 
    * The Epalinges Vaud-based  company is expected to report  a
285.0% increase in revenue to $65.488 million from $17.01
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ADC Therapeutics SA
is
for a loss of 29 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $12​, above​ its last closing price of $4.05. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.30       -0.35      -0.65     Missed  -84.2
 Jun. 30 2022  -0.92       -0.91      -0.84     Beat    8.1
 Mar. 31 2022  -0.69       -0.70      -0.22     Beat    68.4​
 Dec. 31 2021  -0.86       -0.86      -0.45     Beat    47.5
 ​​Sep.        -0.96       -0.92      -0.93     Missed  -1.4
 30 2021                                                
 Jun. 30 2021  -0.87       -0.86      -0.96     Missed  -11.6​
 Mar. 31 2021  -0.92       -0.90      -0.46     Beat    49.2
 Dec. 31 2020  -0.14       -0.38      -1.05     Missed  -173.9
 This summary was machine generated February 24 at 14:04 GMT. 
All figures in US dollars  unless otherwise stated